Immunocore Holdings plc
Research Immunocore Holdings plc (IMCR) on Bullrun: market cap USD 1.90B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIMCR
- ExchangeNASDAQ
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.90B
- Financial periodQ2 2026
- RevenueUSD 115.93M
- Net income-USD 808.00K
- Free cash flowUSD 15.14M
- Gross margin99.1%
Valuation Snapshot
latest market cap is USD 1.90B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 400.02M | -USD 35.51M | -USD 15.05M | 98.7% | -0.71 | USD 467.71M | USD 436.69M | USD 381.03M |
| FY2024 | USD 310.20M | -USD 51.09M | USD 20.89M | 99.1% | -1.02 | USD 455.73M | USD 432.72M | USD 360.72M |
| FY2023 | USD 249.43M | -USD 55.29M | -USD 2.49M | 99.6% | -1.13 | USD 442.63M | USD 85.01M | USD 368.84M |
| FY2022 | USD 174.36M | -USD 52.54M | -USD 51.41M | 99.4% | -1.15 | USD 402.47M | USD 67.69M | USD 338.90M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.90B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.76B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.48B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 3.38B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 2.73B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.50B | n/a | n/a | n/a |
About Immunocore Holdings plc
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Immunocore Holdings plc's market cap?
Immunocore Holdings plc's market capitalization is USD 1.90B.
What does Immunocore Holdings plc do?
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma.